Skip to main content
. 2021 Jun 9;14:3687–3700. doi: 10.2147/OTT.S288788

Figure 6.

Figure 6

miR-210-3p delays the development and metastasis of lung cancer in vivo by inhibiting PCGF3. (A) Real-time qPCR examined the expression of miR-210-3p in tissues of lung cancer xenografts in mice with intravenous injection of miR-210-3p antagomir alone or with sh-PCGF3. (B) Immunoblots and quantification of USF1 and PCGF3 in tissues of lung cancer xenografts in mice with intravenous injection of miR-210-3p antagomir alone or with sh-PCGF3. (C) Growth of lung cancer xenografts in mice with intravenous injection of miR-210-3p antagomir alone or with sh-PCGF3 was monitored every 3 days after implantation duration of 8 days. (D) Histopathological changes (×200) of lung tissues and lymph node metastasis in xenograft mice with intravenous injection of miR-210-3p antagomir alone or with sh-PCGF3. (E) Immunoblots and quantification of Bax, Bcl-2, MMP-2, and MMP-9 in tissues of lung cancer xenografts in mice with intravenous injection of miR-210-3p antagomir alone or with sh-PCGF3. *p < 0.05 compared to NC antagomir + sh-NC and #p < 0.05 compared to miR-210-3p antagomir + sh-NC by ANOVA adjusted by Tukey’s test or by repeated measurements ANOVA adjusted by Bonferroni test (only for C). Sample size of six mice in each study group.